Ken Nelson and Mark Strome Join HeartBeam’s Board

HeartBeam Inc. has appointed Ken Nelson and Mark Strome to its Board of Directors.

“We are privileged to welcome two members with highly relevant backgrounds to HeartBeam’s Board,” HearBeam Founder/CEO Branislav Vajdic, Ph.D., said. “Ken brings extensive experience and insights in cardiac digital health, remote patient monitoring, and medical devices. His firsthand knowledge of our industry will be a critical resource as we progress on our corporate goals. Mark is an experienced investor and business executive who will help us expand the breadth and depth of our reach as a company, positioning us to create additional value for our shareholders. Together, Ken and Mark will contribute a wealth of expertise to the board, adding to the exceptional team that we have elected to guide us forward and commercialize our business.”
 
Nelson, 48, is a 20-year digital health, medical device, and remote patient monitoring executive and innovator. Over the past 10 years, Nelson has led commercial efforts for disruptive technologies in the digital health, wearables, and cardiac remote patient monitoring industries. He’s worked for three of the top four market share players in cardiac digital health and remote patient monitoring, including BioTelemetry as vice president of Sales; iRhythm as vice president of Sales & Marketing; and Bardy Diagnostics as chief commercial officer. Most recently, he was head of Digital Health, Diagnostics, and Monitoring for Biotronik, a cardiac digital health and medical device company.

Nelson is currently a partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator, the largest medtech and digital health startup accelerator globally. In addition, he is board chairman of CardiaCare, and is an active board member in a handful of other cardiac digital health and medtech startups. Nelson earned a bachelor of arts degree in economics from Vanderbilt University.
 
Strome, 66, combines more than 40 years of experience in the investment management and securities industry. He is founder, chief investment officer, and chairman at Strome Investment Management L.P. and Strome Group Inc. Under his leadership, Strome’s investment management company has managed private placement hedge fund investments focusing on non-traditional investments including commodities, currencies, bankruptcy reorganizations, and numerous venture capital and private equity investments. Previously, he was a portfolio manager at Kayne Anderson. He has also been involved in the founding and incubation of numerous publicly traded companies and several successful private companies, including Pulse Biosciences and iWood Studios, a company that creates original content for film and TV.

Strome has been a board member of multiple companies over the last three decades, serving as a director at Endurance Ventures, National Water and Power, Eco-Duro Corporation, NWP Services Corporation, and Mobil Satellite Ventures. He is an Advisory Board member at Global Analytics Inc. and a Trustee for New Roads School and Big Bear Foundation. He also serves on John Hopkins Medical Center’s Board of Advisors. 
 
“I look forward to working with both Mark and Ken, as they are outstanding additions to our board. I am confident that Mark and Ken will offer valuable perspectives as we continue to position the company for the expected clearance and commercialization of the HeartBeam AIMIGo 12-Lead 3D-vector electrocardiogram device,” HeartBeam Board Chairman Richard Ferrari stated.
 
HeartBeam Inc. is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the U.S. Food and Drug Administration.